Patrys has announced it has secured commitments to raise approximately $3.2 million through a share placement that drew strong backing from both new and existing investors.

The initiative marks a significant shift for the company, introducing a dual revenue model that combines its established treatment programs with a new stream of sponsor-funded services built on its existing clinical infrastructure.

Atmo Biosciences has moved to strengthen its United States commercial push, appointing seasoned medtech executive Martin Reid as Senior Vice President, Sales, as the company looks to build on early momentum following regulatory clearance and initial market entry.

5 Horizons Ventures and Biointelect have announced a strategic partnership and investment alliance designed to help promising biotech and medtech ventures navigate one of the most challenging phases of development.

The decision opens the door to approximately 51 military hospitals and 170 VA medical centres, dramatically expanding the company’s reach in the United States and positioning it within systems that routinely handle some of the most challenging trauma cases.

Noxopharm has appointed Dr Olivier Laczka as its new Chief Executive Officer with immediate effect, marking a leadership transition as the clinical-stage company positions itself to capitalise on emerging opportunities in its pipeline.

The therapy is being developed to address the underlying cause of Autosomal Dominant Optic Atrophy, a condition that leads to progressive vision loss and currently has no approved treatment options.

The company has named Chisako Mizutani as Country Manager for Japan, bringing more than two decades of experience in clinical research and leadership in contract research organisations.

The trial, spanning multiple centres across the US, is evaluating the performance of RAD 101 in patients with confirmed recurrent brain metastases from a range of solid tumours.

Australian nuclear medicine company Telix Pharmaceuticals has announced a collaboration with Regeneron to develop new targeted cancer treatments.

Argent BioPharma has completed the acquisition of AusCann Group Holdings' interest in CannPal Animal Therapeutics, marking an important step in strengthening its neurological pipeline and expanding its reach into veterinary medicine.

Clarity Pharmaceuticals (ASX:CU6) has taken another step toward the commercialisation of its prostate cancer imaging agent, signing a manufacturing agreement that significantly broadens its production capacity and geographic reach.

Cartherics and Catalent have strengthened their collaboration to accelerate the development and future commercialisation of advanced immune cell therapies.

Entropy Neurodynamics has taken another step forward in its clinical exploration of psychedelic-assisted therapy, announcing that the third patient in its trial of TRP-8803 has completed dosing and achieved what the company describes as a full and controlled psychedelic response.

The companies said feedback from the initial limited launch suggests that this approach is resonating, with more than 80 per cent of caregivers reporting satisfaction, particularly noting the convenience and portability of individual packet dosing. 

The ten-year contract, valued at up to $25.5 million, is designed to ensure that critical treatment resources are immediately available when large-scale burn incidents occur, a scenario where speed and scalability can determine survival outcomes.

Chairman Russell Howard and Chief Executive Marc Voigt acknowledged the disappointment while emphasising that the broader scientific platform remains intact.